SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:oru-6999"
 

Sökning: onr:"swepub:oai:DiVA.org:oru-6999" > Treatment of primar...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005506naa a2200649 4500
001oai:DiVA.org:oru-6999
003SwePub
008090528s2008 | |||||||||||000 ||eng|
009oai:DiVA.org:umu-46046
009oai:lup.lub.lu.se:258f82f9-f9df-43c4-9dfb-9a04419d274f
009oai:DiVA.org:liu-45900
024a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-69992 URI
024a https://doi.org/10.1111/j.1525-1438.2007.01094.x2 DOI
024a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-460462 URI
024a https://lup.lub.lu.se/record/12549372 URI
024a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-459002 URI
040 a (SwePub)orud (SwePub)umud (SwePub)lud (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Sorbe, Bengtu Örebro universitet,Hälsoakademin,Department of Gynecological Oncology, University Hospital, Örebro, Sweden, Department of Gynecological Oncology, University Hospital, SE-701 85 Örebro, Sweden4 aut0 (Swepub:oru)bse
2451 0a Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up
264 1b Blackwell Publishing Ltd,c 2008
338 a print2 rdacarrier
520 a There is no generally accepted standard chemotherapy in treatment of advanced and recurrent endometrial carcinoma. Cisplatin and doxorubicin with or without cyclophosphamide are widely used. Response rates have improved with combination chemotherapy compared with single-agent therapy. A platinum analog seems to be an important part of the chemotherapy regimen. Since few patients are cured from their disease and since the duration of response is short, further improvement of this therapy is warranted. During the past years, the taxanes (paclitaxel) are being added to prior evaluated regimens and not only improved response rates are reported but also increased toxicity is observed. In a prospective, phase II, multicenter study, carboplatin (area under the curve = 5) and paclitaxel (175 mg/m(2)) were evaluated in treatment of primary advanced and recurrent endometrial carcinoma. In total, 66 patients were recruited during the years 2000-2004. Eighteen primary advanced tumors and 48 recurrences were treated. All histologic types and tumor grades were allowed. The median follow-up was 57 months (range 37-69 months). The overall response rate was 67% (95% CI 55-78). The complete response rate was 29% and the partial response rate 38%. Primary advanced and recurrent tumors as well as endometrioid and nonendometrioid tumors showed similar response rates. The median response duration was 14 months. The 1- and 3-year survival rates were 82% and 33%, respectively. The main toxicities were hematologic and neurologic (sensory neuropathy). The response rates were encouraging, superior to prior platinum-containing regimens, but response duration and the long-term survival rate were still short. The neurologic toxicity was frequent and was a substantial problem in this series of patients. Further research is highly needed to improve the treatment of advanced and recurrent endometrial cancer.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reproduktionsmedicin och gynekologi0 (SwePub)302202 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Obstetrics, Gynaecology and Reproductive Medicine0 (SwePub)302202 hsv//eng
653 a Taxol
653 a carboplatin
653 a endometrial cancer
653 a MEDICINE
653 a MEDICIN
653 a Oncology
653 a Onkologi
653 a Obstetrics and gynaecology
653 a Obstetrik och gynekologi
653 a Oncology
653 a onkologi
653 a chemotherapy
653 a carboplatin
653 a paclitaxel
653 a endometrial cancer
700a Andersson, Hu Department of Gynecological Oncology, University Hospital, Gothenburg, Sweden4 aut
700a Boman, Karinu Umeå universitet,Onkologi,Department of Gynecological Oncology, University Hospital, Umeå, Sweden4 aut0 (Swepub:umu)kabo0010
700a Rosenberg, Peru Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US4 aut0 (Swepub:liu)perro95
700a Kalling, Mårtenu Lund University,Lunds universitet,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Gynecologic Oncology, University Hospital, Lund, Sweden4 aut0 (Swepub:lu)extLU-138
710a Örebro universitetb Hälsoakademin4 org
773t International Journal of Gynecological Cancerd : Blackwell Publishing Ltdg 18:4, s. 803-808q 18:4<803-808x 1048-891Xx 1525-1438
856u http://dx.doi.org/10.1111/j.1525-1438.2007.01094.xy FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-6999
8564 8u https://doi.org/10.1111/j.1525-1438.2007.01094.x
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-46046
8564 8u https://lup.lub.lu.se/record/1254937
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-45900

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy